| Literature DB >> 15315837 |
Selman A Ali1, Murrium Ahmad, June Lynam, Cornelia S McLean, Claire Entwisle, Peter Loudon, Esther Choolun, Stephanie E B McArdle, Geng Li, Shahid Mian, Robert C Rees.
Abstract
OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4+ and CD8+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15315837 DOI： 10.1016/j.vaccine.2004.03.041
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641